HIV type 1 protease inhibitors enhance bone marrow progenitor cell activity in normal subjects and in HIV type 1-infected patients.
HIV-1 protease inhibitors (PIs) may improve hematopoietic functions owing to their direct effects on bone marrow (BM) progenitor cells. In this study we investigated this hypothesis evaluating the effect of adding ritonavir (RTV) and indinavir (IND) on hematopoietic colony formation assays by colony-forming cell (CFC) and long-term culture-initiating cell (LTC-IC) assays, on apoptosis, on cytokine production and stromal cells, in subjects with HIV-1 infection, and in seronegative controls. After PI addition, CFC and LTC-IC assays in HIV-1-infected patients showed levels of colony growth significantly higher than those observed at baseline; the same PI activity on colony formation was observed in healthy subjects. No significant modifications on Fas, the membrane form of Fas (mFas) and Fas-ligand (FasL) expression, and on cytokine production were observed at BM level after the addition of PIs. At baseline, in HIV-1-infected patients, the majority of the stromal cells appeared as large and rounded, whereas after the addition of RTV or IND the stromal cells exhibited a "fibroblast-like" morphology and produced higher stem cell factor (SCF) and lower MIP-1alpha levels when compared with the stromal production without the addition of IND. RTV and IND increased colony growth of BM obtained either from HIV-1-infected patients or from normal individuals, in parallel with the normalization of functional and morphological characteristics of stromal cells.
Isgrò
Antonella
A
Division of Allergy and Clinical Immunology, University of Rome "La Sapienza," 00185 Rome, Italy.
Aiuti
Alessandro
A
Mezzaroma
Ivano
I
Ruco
Luigi
L
Pinti
Marcello
M
Cossarizza
Andrea
A
Aiuti
Fernando
F
D000328:Adult; D017209:Apoptosis; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects*; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D005260:Female; D015658:HIV Infections; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D018023:HIV Seronegativity; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D019469:Indinavir / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000494:pharmacology*; D017154:Stromal Cells
D016207:Cytokines; D017320:HIV Protease Inhibitors; D019469:Indinavir; D019438:Ritonavir